-
Cabozantinib, sold
under the
brand names Cometriq and
Cabometyx among others, is an anti-cancer
medication used to
treat medullary thyroid cancer, renal...
-
partnered its lead
cancer drug candidate, XL-184 (which
would become called cabozantinib) and
another cancer candidate, XL-281, with
Bristol Myers Squibb; BMS...
- surgery.
Cabozantinib,
trade name Cometriq, was
granted marketing approval (November 2012) by the U.S. FDA for this indication.
Cabozantinib which is...
- daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib,
cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib...
- Institute. His work has led to the
establishment of
several novel drugs (
cabozantinib, avelumab,
pazopanib and
others including combinations) and prognostic...
-
cancer (MTC) who
require systemic therapy following prior treatment with
cabozantinib and/or vandetanib.
Selpercatinib can
cause serious side
effects including...
- that it is due to the
decreased absorption of
abacavir by orlistat.
Cabozantinib:
Drugs from the MRP2
inhibitor (Multidrug resistance-****ociated protein...
-
common adverse reaction to
cytotoxic chemotherapy drugs,
particularly cabozantinib, cytarabine, doxorubicin, and
fluorouracil and its
prodrug capecitabine...
-
spasticity in
children aged two
years and older. In 2016,
Ipsen licensed cabozantinib from Exelixis,
which received marketing authorization the same year for...
- (PNB-0408)
Kinase inhibitors:
Altiratinib AM7 AMG-458
Amuvatinib BMS-777607
Cabozantinib Capmatinib Crizotinib Foretinib Golvatinib INCB28060 JNJ-38877605 K252a...
